Preclinical evaluation of the antineoplastic action of 5-aza-2′-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells

Cancer Cell International

Volumn 8, Issue , 2008, Pages

  Hurtubise, Annie ^a,c   Bernstein, Mark L ^b   Momparler, Richard L ^a,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ARYLBUTYRIC ACID DERIVATIVE; DEPSI; F 901228; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; ROMIDEPSIN; TRICHOSTATIN A; TUMOR SUPPRESSOR LUNG CANCER PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG POTENTIATION; EWING SARCOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; TUMOR SUPPRESSOR GENE;

EID: 57749179753     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-8-16     Document Type: Article

References (19)

1. Bernstein M Kovar H Paulussen M Randall RL Schuck A Teot LA Juergens H Ewing's sarcoma family of tumors: Current management Oncologist 2006, 11:503-519 10.1634/theoncologist.11-5-503 16720851
2. Jones PA Baylin S The fundamental role of epigenetic events in cancer Nat Rev Genet 2002, 3:415-28 10.1038/nrg962 12042769
3. Momparler RL Pharmacology of 5-Aza-2′-deoxycytidine (decitabine) Semin Hematol 2005, 42:S9-16 10.1053/j.seminhematol.2005.05.002 16015507
4. Issa JP Issa JP Garcia-Manero G Giles FJ Mannari R Thomas D Faderl S Bayar E Lyons J Rosenfeld CS Cortes J Kantarjian HM Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 2004, 103:1635-1640 10.1182/blood-2003-03-0687 14604977
5. Lübbert M Wijermans P Kunzmann R Verhoef G Bosly A Ravoet C Andre M Ferrant A Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine Br J Haematol 2001, 114:349-357 10.1046/ j.1365-2141.2001.02933.x 11529854
6. Marks P Rifkind RA Richon VM Breslow R Miller T Kelly WK Histone deacetylases and cancer: Causes and therapies Nat Rev Cancer 2001, 1:194-202 10.1038/35106079 11902574
7. Conley BA Wright JJ Kummar S Targeting epigenetic abnormalities with histone deacetylase inhibitors Cancer 2006, 107:832-840 10.1002/ cncr.22064 16826577
8. Peart MJ Tainton KM Ruefli AA Dear AE Sedelies KA O'Reilly LA Waterhouse NJ Trapani JA Johnstone RW Novel mechanisms of apoptosis induced by histone deacetylase inhibitors Cancer Res 2003, 63:4460-4471 12907619
9. Drummond DC Noble CO Kirpotin DB Guo Z Scott GK Benz CC Clinical development of histone deacetylase inhibitors as anticancer agents Annu Rev Pharmacol Toxicol 2005 45 495 528 10.1146/ annurev.pharmtox.45.120403.095825 15822187
10. Cameron EE Bachman KE Myohanen S Herman JG Baylin SB Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 1999, 21:103-107 10.1038/5047 9916800
11. Primeau M Gagnon J Momparler RL Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells Intl J Cancer 2003, 103:177-184 10.1002/ijc.10789
12. Boivin A-J Momparler LF Hurtubise A Momparler RL Antineoplastic action of 5-aza-2′-deoxycytidine and phenylbutyrate on human lung carcinoma cells Anti-Cancer Drugs 2002, 13:869-874 10.1097/ 00001813-200209000-00013 12394273
13. Nam JS Ino Y Kanai Y Sakamoto M Hirohashi S 5-aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis Clin Exp Metastasis 2004, 21:49-56 10.1023/ B:CLIN.0000017180.19881.c1 15065602
14. Hui AB Lo KW Kwong J Lam EC Chan SY Chow LS Chan AS Teo PM Huang DP Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma Mol Carcinog 2003, 38:170-178 10.1002/mc.10156 14639656
15. Valeriote F Lin H Synergistic interaction of anticancer agents: A cellular perspective Cancer Chemother Rep 1975, 59:895-900 1203896
16. Momparler RL Ayoub J Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer Lung Cancer 2001, 34:S111-115 10.1016/S0169-5002(01)00397-X 11742714
17. Jaboin J Wild J Hamidi H Khanna C Kim CJ Robey R Bates SE Thiele CJ MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors Cancer Res 2002, 62:6108-6115 12414635
18. Eyüpoglu IY Hahnen E Tränkle C Savaskan NE Siebzehnrübl FA Buslei R Lemke D Wick W Fahlbusch R Blümcke I Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol Cancer Ther 2006, 5:1248-1255 10.1158/1535-7163.MCT-05-0533 16731757
19. Kummar S Gutierrez M Gardner ER Donovan E Hwang K Chung EJ Lee MJ Maynard K Kalnitskiy M Chen A Melillo G Ryan QC Conley B Figg WD Trepel JB Zwiebel J Doroshow JH Murgo AJ Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies Clin Cancer Res 2007, 13:5411-5417 10.1158/ 1078-0432.CCR-07-0791 17875771